Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-791325 QT Study in Healthy Subjects
NCT02084953Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2014
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of beclabuvir in hepatitis C (HCV) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: QT interval corrected for Fridericia's method at Day 3. Started Apr 2014; status: completed.
02
Drugs
beclabuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02084953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02084953.